New hope for lung cancer patients with brain spread: targeted pill under study
NCT ID NCT06282874
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the brain and spinal cord. The goal is to see how well the drug shrinks these brain tumors. About 41 participants will take lorlatinib once daily, and researchers will track their response and how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorlatinib (a targeted cancer pill)
What this could lead to
If it works, this could offer a more effective treatment option for lung cancer that has spread to the brain or spinal cord, potentially improving survival and quality of life.
What could go wrong
This is a small, single-arm study (no comparison group), so results may not be definitive. Side effects of lorlatinib can include liver problems, high cholesterol, and swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial Perople's Hospital
Guangzhou, Guangdong, 510080, China
-
Tenth Affiliated Hospital, Southern Medical University (Dongguan people's hospital)
Dongguan, Guangdong, 510080, China
-
The First People's Hospital of Foshan
Foshan, Guangdong, 510080, China